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versus DRV/r. CONCLUSIONS: The value of initiation with ATV/r in terms of dura-
ble viral suppression and favourable side-effect profile was most prominent in
Spain. In general, starting with ATV/r is suggested to be a cost-effective treatment
strategy for HIV-1 treatment-naïve patients in most of the country-specific com-
parisons made.
PIN74
A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH 23-
VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN GERMANY
Jiang Y1, Gauthier A1, Annemans L2, van der Linden M3, Nicolas-Spony L4, Bresse X4
1Amaris Consulting UK, London, UK, 2Ghent University, Ghent, Belgium, 3National Reference
Centre for Streptococci, Aachen, Germany, 4Sanofi Pasteur MSD, Lyon, France
OBJECTIVES: Streptococcus pneumoniae is a leading cause of life-threatening pneu-
mococcal diseases (PDs). In Germany, PPV23 has been recommended in the elderly
(aged 60 and over) since 1998. In 2006, the pneumococcal conjugate vaccine (PCV)
was introduced in children. The US experience showed that PCV vaccination of
children led, ten years after its introduction, to a decrease in IPD incidence caused
by the PCV serotypes not only in vaccinated children but also in unvaccinated
adults. This study aimed to re-assess the good cost-effectiveness profile of PPV23
vs. no vaccination (NoVac) in the elderly in Germany, accounting for epidemiolog-
ical changes in adults due to PCV vaccination of children.METHODS:A population-
based Markov model was developed, consisting of five health states: no PD, IPD
(invasive PD), NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis
sequelae (PMS) and death. A cohort of individuals was followed until death assum-
ing vaccination or no vaccination. IPD and NBPP incidence were retrieved from
German sources, while the changes in IPD incidence were estimated based on US
data. IPD and NBPP case-fatality rates, probability of developing PMS, vaccine ef-
fectiveness, vaccine waning function and utilities were retrieved from the pub-
lished literature. A discount rate of 3% was applied to costs and effects. RESULTS:
PPV23 was associated with a discounted increment of 1,587 QALYs. From the third
party payer’s (TPP) perspective, incremental costs were estimated at €28 million
and the ICER was €17,700/QALY gained. From the societal perspective, PPV23 was
associated with an increment of €14 million, and the ICER was €8579/QALY gained.
Results were sensitive to vaccine effectiveness and epidemiological trends
assumptions. CONCLUSIONS: The model suggests that vaccinating the elderly
with PPV23 is cost-effective in Germany. As PPV23 covers 80%-90% of all serotypes
causing IPD, it is still cost-effective despite the reduction in IPD incidence in adults
due to PCV vaccination of children.
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Vaccination of elderly (65 and older) population against Streptococcus pneumonia
is recommended in Poland but not publicly funded. Therefore coverage rates for
pneumococcal vaccine have remained very low (less than 1%) meaning that no
benefit of the vaccine has been felt in Poland and individuals remain largely
unprotected. OBJECTIVES: An analysis was designed to analyse the cost-effective-
ness of implementing a public vaccination programme in the elderly considering a
50% reimbursement of a 23-valent polysaccharide vaccine (PPV23) by the public
health care payer: Narodowy Fundusz Zdrowia (NFZ). METHODS: To do so, a semi-
dynamic Markov model with a 1-year cycle length was developed, allowing up to 10
cohorts to enter the model over the lifetime horizon. The model was populated
with demographic, epidemiological and cost data from Polish sources or when
unavailable, from international literature. The analysis included routine vaccina-
tion of all elderly or high-risk (HR) elderly versus no vaccination. Deterministic and
probabilistic sensitivity analyses (DSA and PSA, respectively) were conducted to
assess the robustness of the cost-effectiveness results. RESULTS: The vaccination
program targeting all elderly in Poland would avoid 8935 pneumococcal infections,
2542 hospitalisations, 671 deaths; for HR elderly the program would avoid 5886
infections, 1673 hospitalisations and 441 deaths. The incremental cost per QALY
gained for vaccination in all elderly was PLN 3382 and was PLN 2148 for HR elderly.
Ratios were even lower when actual in and outpatients’ costs instead of reim-
bursed costs were considered. Finally, ratios estimated in the base case and the
sensitivity analyses, were well below the gross domestic product (GDP) per capita
(i.e. PLN 37,055). CONCLUSIONS: This analysis suggests that vaccinating all elderly
regardless of risk status with a 23-valent pneumococcal vaccine is highly cost-
effective and supports the continued recommendation of pneumococcal vaccines,
as well as their public funding in Poland.
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OBJECTIVES: According to World Health Organization, pneumococcal related dis-
eases is a major public health concern in the world, especially for those under 2
years of age and older adults. The objective of this analysis is to evaluate the cost
effectiveness of vaccinating the Brazilian population 65 years of age and older with
the 13-valent pneumococcal conjugate vaccine (PCV 13) in comparison to the 23-
valent pneumococcal polysaccharide vaccine (PPV 23), each as a single dose, from
the public payer perspective. METHODS: In order to estimate the costs and the
impact of the pneumococcal disease over a 35-year time horizon period, including
invasive pneumococcal disease, hospitalized pneumonia and non complicated
pneumonia, a patient level microsimulation model simulating vaccination and
outcomes of one cohort of 12,653,613 individuals over 65 years of age was adapted
to the Brazilian public health care system. The probabilities and direct medical
costs were extracted from literature review and DATASUS for January 2011, with
costs presented in US$ 2010. The effectiveness measures were expressed as cases
of pneumococcal diseases avoided, overall deaths avoided, and life years (LYs)
saved. Probabilistic sensitivity analyses were conducted considering key variables.
A discount rate of 5% was applied. RESULTS: Vaccinating with PCV13 prevents 349
additional cases of acute meningitis, 1,589 cases of invasive pneumococcal disease,
100,158 hospitalized pneumonia, 12,954 non complicated pneumonia and 30,904
deaths, saving 139,189,74 LYs compared to PPV23 over 35 years. The total costs
including vaccination costs and medical costs resulted in US$135,625,000 less for
PCV13 compared to PCV23 (US$5,875,625,000 vs. US$5,740,000,000). The model
showed robustness through sensitivity analyses.CONCLUSIONS:The analysis sug-
gests that vaccinating adults with PCV13 in Brazil is cost-saving compared to
PPV23. The results in economic and disease burden are substantial and they sup-
port the decision making in favor of PCV13 for its high impact in public health.
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OBJECTIVES: Systemic Candida infections (SCI) occur predominantly in intensive
care unit (ICU) patients and are a common cause of morbidity and mortality. The
increasing prevalence of SCI caused by Candida non-albicans species and higher
resistance to fluconazole and azoles in general have prompted changes in the
management of SCI. Current guidelines tend to favour treatment initiation with a
broad spectrum antifungal such as an echinocandin with subsequent switch to
fluconazole if isolates are sensitive (de-escalation) over the traditional first-line
treatment with fluconazole (escalation). Cost-effectiveness of de-escalation strat-
egy versus escalation in patients with SCI was evaluated from the UK NHS
perspective. METHODS: Cost-effectiveness was estimated using decision analysis
based on clinical and microbiological data from pertinent studies. The model ho-
rizon was 42 days, and was extrapolated to cover a life time horizon. RESULTS: In
patients with fluconazole-resistant isolates, de-escalation avoids 30% more deaths
and successfully treats 23% more patients than escalation, with cost savings of
£1621 per treated patient. In the overall population with SCI, initial treatment with
micafungin results in 1.2% fewer deaths at a marginal cost of £740 per patient alive.
Over a lifetime horizon, the incremental cost effectiveness of de-escalation com-
pared with escalation is £15,522 per life-year and £25,673 per QALY. Univariate
analyses indicate that the incremental costs per QALY of de-escalation are highly
sensitive to the fluconazole-susceptibility profile, late mortality in fluconazole-
resistant infections, fluconazole clinical success rate, excess hospitalization, life
expectancy, underlying diseases and follow-up costs. CONCLUSIONS: The de-es-
calation strategy is associated with better clinical outcomes and improved survival,
particularly among patients with fluconazole-resistant Candida strains. De-esca-
lation from initial treatment with micafungin is a cost effective alternative to tra-
ditional escalation approach from a UK NHS perspective with a differential cost per
QALY below the recognised willingness to pay threshold of £30,000.
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OBJECTIVES: Respiratory syncytial virus (RSV) infection is one of the major causes
of respiratory symptoms in infants in many countries, infecting virtually every
child by the age of two. Currently, several Phase 1 trials with RSV vaccines in
infants are running or have been completed. Although no efficacy estimates are yet
available, cost-effectiveness estimates might be informative enabling preliminary
positioning. METHODS: A decision analysis model was developed following a
Dutch birth cohort for 12 months. Vaccination strategies that were reviewed in-
cluded vaccination at specific ages, different dosing schemes and seasonal versus
year round vaccination. The impact of the assumptions was explored in sensitivity
analyses. Outcome measures included number of GP visits, hospitalizations and
deaths, costs, quality-adjusted life years and ICERs. RESULTS: Without vaccina-
tion, an annual number of 28,738 of RSV-related GP visits, 1,623 hospitalizations,
and 4.5 deaths are estimated in the 0-1 year olds. The total cost to society in the
non-vaccination scenario was €7.7 million and the annual disease burden was
estimated at 597 QALYs. In case all infants would be offered a 3-dose RSV vaccina-
tion scheme at 0/1/3 months of age, the total annual net costs were estimated to
increase to €21.2 million but a significant number of hospitalizations and deaths
could be averted, 544 and 1.5 respectively. The ICER was estimated € 34,142 (95%CI:
€ 21,652 - € 87,766) per QALY. A reduced dose schedule, seasonal vaccination, out-of
pocket payments all resulted in a more favorable ICERs while lowering the ex-
pected vaccine efficacy or delaying the time of vaccination in less favorable ICERs.
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